GeneDx Holdings Corp.
WGS Nasdaq· Services-Health Services
Last close · Oct 23, 2026
$56.15
KIRA · Stoqly’s AI analyst, in plain words
- GeneDx Holdings Corp. had $428M of revenue in fiscal 2025, up 40.0% on the year before. Over five years, revenue changed +19.0% a year on average.
- Its operating margin was −3.1%, up 4.5 pts: of every 100 in sales, about −3 is left after running the business.
- GeneDx Holdings Corp. lost $21.0M in fiscal 2025.
- Free cash flow was $14.3M in fiscal 2025, 3.3% of revenue.
- GeneDx Holdings Corp. has $98.9M more cash than debt.
Market cap
$1.7B
P/E
—
Revenue
$428M
Net income
−$21.0M
Free cash flow
$14.3M
Operating margin
−3.1%
GeneDx Holdings Corp. in 30 seconds · fiscal 2025
Are sales growing?
+40.0%
Yes. Sales grew 40.0% last year.
Does it make a profit?
−4.9%
No. It lost money last year.
Does profit turn into cash?
3.3%
Partly. 3.3% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What GeneDx Holdings Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- GeneDx Holdings Corp.
- CIK
- 0001818331
GeneDx Holdings Corp. · WGS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $212M | $235M | $203M | $305M | $428M |
| Revenue growth | 18.3% | 10.6% | −13.7% | 50.8% | 40.0% |
| Net interest income | — | −$0.7M | $1.1M | — | — |
| Gross margin | −7.8% | −11.4% | 44.4% | 63.6% | 69.7% |
| Operating margin | −210.3% | −284.5% | −89.2% | −7.6% | −3.1% |
| Net income | −$245M | −$549M | −$176M | −$52.3M | −$21.0M |
| Net margin | −115.6% | −233.9% | −86.8% | −17.1% | −4.9% |
| Diluted EPS | −$2.27 | −$53.63 | −$7.23 | −$1.94 | −$0.73 |
| Cash | |||||
| Cash from operations | −$190M | −$319M | −$180M | −$28.5M | $33.3M |
| Capital expenditure | $9.4M | $7.2M | $5.3M | $5.5M | $19.0M |
| Free cash flow | −$200M | −$326M | −$185M | −$34.0M | $14.3M |
| FCF margin | −94.2% | −139.0% | −91.5% | −11.1% | 3.3% |
| Share count change | 2,119,064.7% | −90.5% | 137.5% | 10.6% | 6.5% |
| Debt and strength | |||||
| Cash and short-term investments | $401M | $124M | $130M | $141M | $171M |
| Debt incl. finance leases | $11.0M | $30.3M | $76.1M | $74.7M | $72.3M |
| Shareholders' equity | $388M | $254M | $228M | $245M | $308M |
| Current ratio | 4.8x | 1.5x | 3.1x | 3.6x | 2.5x |
| Interest coverage | −157.4x | −208.2x | — | — | — |
| Returns and quality | |||||
| Return on capital | — | −374.7% | −92.6% | −11.5% | −5.4% |
| Return on equity | −845.4% | −171.1% | −73.0% | −22.1% | −7.6% |
| Return on tangible equity | −63.2% | −818.7% | −317.3% | −60.3% | −16.7% |
| Piotroski F-score | 4 | 3 | 4 | 6 | 6 |
| Altman Z'' | −1.8 | −14.6 | −9.8 | −7.2 | −5.2 |
Insiders bought, 12 months
$107M
3 insiders
Insiders sold, 12 months
$21.8M
4 insiders
Of sales under plans
2%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GeneDx Holdings Corp. · WGS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $56.15 a share, the company is worth $1.7B.
Source: SEC EDGAR XBRL filings (CIK 0001818331). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.